The historical rank and industry rank for Carna Biosciences's Days Payable or its related term are showing as below:
TSE:4572'
s Days Payable Range Over the Past 10 Years
Min: 2.37 Med: 3.94 Max: 63.48
Current: 3.93
During the past 13 years, Carna Biosciences's highest Days Payable was 63.48. The lowest was 2.37. And the median was 3.94.
TSE:4572's Days Payable is ranked worse than 99.15% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs TSE:4572: 3.93
Carna Biosciences's Days Payable
declined
from Jun. 2024 (3.05) to Dec. 2025 (0.00).
It may suggest that Carna Biosciencesaccelerated paying its suppliers.
Carna Biosciences Days Payable Related Terms
Carna Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Carna Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4572 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Carna Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carna Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Carna Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Carna Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Carna Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences (TSE:4572) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carna Biosciences and its competitors. Over the past decade, Carna Biosciences' Days Payable has ranged from 2.37 to 63.48. According to the industry distribution chart, Carna Biosciences ranks #696 out of 702 companies in the Biotechnology industry, placing it in the top 99.1%.
Is Carna Biosciences' Days Payable too high?
Carna Biosciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 63.48. Based on the distribution chart, Carna Biosciences ranks #696 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Carna Biosciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Carna Biosciences ranks #696 out of 702 companies for Days Payable. This places Carna Biosciences in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Carna Biosciences' own Days Payable has ranged from 2.37 to 63.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carna Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carna Biosciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円174.75, compared to a current price of 円337.00 — trading 92.8% above its estimated fair value. The current Days Payable is 0.00. Carna Biosciences' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円337.00 is trading 92.8% above its estimated GF Value™ of 円174.75.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Days Payable: 0.00
GF Value™: 円174.75 vs. price of 円337.00 (92.8% above fair value)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
24GF Score
Get the complete analysis for TSE:4572
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
